MUC16 and ovarian cancer: While further development and validation of the plethora of emerging biomarkers will undoubtedly take time, the failure of CA125- and TVU-based screening trials has led to a renewed emphasis on improving clinical trial design to more efficiently identify approaches with the potential to effectively reduce ovarian cancer mortality [287].